Cited by 334Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia

Open access
Mesulam, M.-Marsel, Weintraub, Sandra, Rogalski, Emily J., Wieneke, Christina, Geula, Changiz, Bigio, Eileen H.·2014·Brain

Abstract

Fifty-eight autopsies of patients with primary progressive aphasia are reported. Twenty-three of these were previously described (Mesulam et al., 2008) but had their neuropathological diagnoses updated to fit current criteria. Thirty-five of the cases are new. Their clinical classification was guided as closely as possible by the 2011 consensus guidelines (Gorno-Tempini et al., 2011). Tissue diagnoses included Alzheimer's disease in 45% and frontotemporal lobar degeneration (FTLD) in the others, with an approximately equal split between TAR DNA binding protein 43 proteinopathies and tauopathies. The most common and distinctive feature for all pathologies associated with primary progressive aphasia was the asymmetric prominence of atrophy, neuronal loss, and disease-specific proteinopathy in the language-dominant (mostly left) hemisphere. The Alzheimer's disease pathology in primary progressive aphasia displayed multiple atypical features. Males tended to predominate, the neurofibrillary pathology was more intense in the language-dominant hemisphere, the Braak pattern of hippocampo-entorhinal prominence was tilted in favour of the neocortex, and the APOE e4 allele was not a risk factor. Mean onset age was under 65 in the FTLD as well as Alzheimer's disease groups. The FTLD-TAR DNA binding protein 43 group had the youngest onset and fastest progression whereas the Alzheimer's disease and FTLD-tau groups did not differ from each other in either onset age or progression rate. Each cellular pathology type had a preferred but not invariant clinical presentation. The most common aphasic manifestation was of the logopenic type for Alzheimer pathology and of the agrammatic type for FTLD-tau. The progressive supranuclear palsy subtype of FTLD-tau consistently caused prominent speech abnormality together with agrammatism whereas FTLD-TAR DNA binding protein 43 of type C consistently led to semantic primary progressive aphasia. The presence of agrammatism made Alzheimer's disease pathology very unlikely whereas the presence of a logopenic aphasia or word comprehension impairment made FTLD-tau unlikely. The association of logopenic primary progressive aphasia with Alzheimer's disease pathology was much more modest than has been implied by results of in vivo amyloid imaging studies. Individual features of the aphasia, such as agrammatism and comprehension impairment, were as informative of underlying pathology as more laborious subtype diagnoses. At the single patient level, no clinical pattern was pathognomonic of a specific neuropathology type, highlighting the critical role of biomarkers for diagnosing the underlying disease. During clinical subtyping, some patients were unclassifiable by the 2011 guidelines whereas others simultaneously fit two subtypes. Revisions of criteria for logopenic primary progressive aphasia are proposed to address these challenges.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awu024

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In behavioural or dysexecutive variants, corticobasal syndrome, and semantic or non-fluent variants of primary progressive aphasia, positive Alzheimer's disease biomarkers are particularly ambiguous and can be considered either as Alzheimer's disease copathology or atypical forms of Alzheimer's disease.

    “This biomarker positivity is particularly ambiguous in the case of behavioural or dysexecutive variants, corticobasal syndrome, and semantic or non-fluent variants of primary progressive aphasia, in which the presence of positive Alzheimer’s disease biomarkers can be considered either as Alzheimer’s disease copathology or atypical forms of Alzheimer’s disease94,96,98,99 (appendix p 2).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Rohrer JD, Rossor MN, Warren J. Alzheimer pathology in primary pro- gressive aphasia. Neurobiol Age 2012; 33: 744-52.
  2. Sajjadi SA, Patterson K, Arnold RJ, Watson PC, Nestor PJ. Primary pro- gressive aphasia: a tale of two syndromes and the rest. Neurology 2012; 78: 1670-7.
  3. Thompson CK, Shapiro LP, Tait ME, Jacobs B, Schneider SL, Ballard K. A system for the linguistic analysis of agrammatic language production. Brain Lang 1995; 51: 124-9.

Cited by

Sorted by citations

Authors
Mesulam, M.-M., Weintraub, S., Rogalski, E. J., Wieneke, C., Geula, C., & Bigio, E. H.
Affiliations
Northwestern University (US)
Corresponding author
Mesulam, M.-Marsel
Venue
Brain
Published
2014-02-25
Volume
137
Issue
4
Pages
1176-1192
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2150070900
Cited by
334
References
67
Citations by year
2026: 12 · 2025: 21 · 2024: 16 · 2023: 17 · 2022: 34 · 2021: 40 · 2020: 37 · 2019: 33 · 2018: 36 · 2017: 23 · 2016: 30 · 2015: 22 · 2014: 13
FWCI
22.40
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (AG13854, P30AG013854)
  • National Institute on Deafness and Other Communication Disorders (R01DC008552, DC008552)
  • National Institute of Neurological Disorders and Stroke (R01NS075075)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
primary progressive aphasia, Alzheimer's disease, frontotemporal lobar degeneration, tauopathy, progressive supranuclear palsy, semantic dementia, logopenic aphasia, agrammatism, neurofibrillary pathology, APOE ε4, age of onset, disease progression
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Autopsy, Brain, Female, Humans, Male, Middle Aged, Aphasia, Primary Progressive, Frontotemporal Lobar Degeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review